Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 30 September 1996
Commenting on the clinical trial process, Edward L. Gallup, President of Immucor, Inc. said, "The clinical trials are expected to take approximately six to eight weeks to complete, and if successful, the Company will submit a 510(k) application to the U.S. Food and Drug Administration for market clearance, and begin non-U.S. marketing this winter."
Commenting further, Mr. Gallup noted, "While the ABS2000 is ideal for patient testing in the hospital transfusion service, we recognized a growing market need for a second analyzer in high volume blood donor centers and clinical reference laboratories. Applying the same work flow solutions developed for the hospital laboratory with the ABS2000 -- automating current manual procedures to minimize technologist hands-on time, and positive sample identification to reduce the potential for technologist transcription errors -- we targeted a second development effort called the ABS(HV). If the project proves successful, the ABS(HV) will offer blood donor centers, clinical laboratories and high volume transfusion services automated batch processing and positive sample identification of routine blood donor tests, specifically blood group antibody screening, syphilis screening and cytomegalovirus (CMV) screening."
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. Capitalizing on its patented and proprietary Capture(R) product technology, the Company has also developed two transfusion service laboratory analyzers to automate certain labor intensive, time consuming blood tests currently performed manually by laboratory technologists.
CONTACT: Richard J. Still, Senior Vice President - Finance, Immucor, Inc., 770-441-2051
Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
960930
PR960935
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .